Monday, September 12th, 2016

Multiple Sclerosis (MS) is a condition caused due to myelin damage that disrupts the impulse communication between the brain and rest of the body. Multiple Sclerosis  (MS) is commonly observed in women between the ages of 20 to 50 years. According to the Multiple Sclerosis Foundation, approximately, ~2.5 million people are affected from multiple sclerosis. Increasing initiatives from the government for favourable reimbursements, rise in the number of R & D activities ofpharmaceutical companies and increasing incidences of MS are major factors responsible for the growth of the market. Moreover, pharmaceutical companies are targeting the Asia-Pacific region through research and development to commercialize drugs at affordable pricing.

This would provide a competitive advantage for the Asia-pacific MS drugs market. However, the side effects associated with therapeutics and unaffordable cost of drugs would limit the market growth. Nevertheless, the leading pharmaceutical companies operating in North America and Europe is shifting the focus on Asia-pacific region due to the growing demand for effective and economic MS treatment.

Request a Brochure of This Report, here:

Pharmaceutical companies belong to developed regions are focusing on the commercialization of novel therapeutics having minimal side effects and economic pricing. Such product launch strategy would provide an opportunity for the pharmaceutical companies across developing economies. Furthermore, the market is majorly supplemented by increasing funding from government authorities for research and development.

The global multiple sclerosis market is segmented into, treatment modality and geography. Based on treatment modality of multiple sclerosis, the market is categorized intoinjectable agents and oral agents. Geographically, the report is segmented across four regions namely, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies majority of the market share followed by Europe and the Asia Pacific region. Product launch is the key strategy adopted by leading players operating in this market.

Do Inquiry Before Purchasing Report:

The companies are building their core competencies by introducing novel therapeutics agents with minimal side effects. In 2013, Biogen Idec introduced Tecfidera, which is a safer and effective treatment as compared to the use of earlier drugs. This drug has reduced the annualized relapse rate (ARR) for MS patients by 44%, previously evaluated at 52% on the consumption of Gilenya. Companies profiled in this report include Biogen Idec, Novartis, EMD Serono, Sanofi, Teva Pharmaceutical, Bayer, Pfizer, Synthetic Biologic, Active Biotech, and Opexa.

Multiple Sclerosis Market - By treatment modality

  • Injectable agents
  • Oral agents

File Library

Contact Profile

Intense Research

Intense Research is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations. Intense Research is the comprehensive collection of market intelligence products and services available on air. We have market research reports from number of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.

Joel John
P: 18554654651
M: 18554654651


Multiple Sclerosis Market, Multiple Sclerosis Industry, Multiple Sclerosis Market 2016,Global Multiple Sclerosis Market




More Formats

View QR Code